EOM 1352: Fri 7 June 2024, 11:36
Media Pack
News

Current Edition

Volume 17 Issue 4
Discovery Park: Wed 13 November 2024, 10:35
ramusmedical
Regional News

Salvat heads to regulators with phase 3 data on ocular steroid

Salvat is gearing up to launch an ocular corticosteroid treatment for inflammation and pain in cataract surgery patients after finishing phase 3 trials and starting t...
13 April 2022 Regional News ocular | Phase 3
Continue Reading →
Europe

Lilly to Present Phase 3 Data at AHS 2018 Highlighting Innovative Potential Treatments for Migraine and Cluster Headache

Eli Lilly and Company (NYSE: LLY) announced today it will present Phase 3 data for galcanezumab and lasmiditan, two investigational, non-opioid treatments for migra...
27 June 2018 Europe 2018 | AHS
Continue Reading →
Europe

New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent® (dupilumab) improved moderate-to-severe asthma

Results showed Dupixent demonstrated a significant improvement in multiple asthma endpoints in two Phase 3 clinical trials in a broad population of patients with ...
23 May 2018 Europe | North America Duxipient | England
Continue Reading →
news

Discontinuation of Sanofi’s C. difficile Vaccine Program presents an opportunity for Pfizer and Valneva, observes GlobalData

On December 1 2017, Sanofi Pasteur announced its intention to discontinue the Phase III development program for its Clostridium difficile vaccine. The vaccine was on ...
20 December 2017 news clostridium difficile | late-stage clinical
Continue Reading →
news

Ozanimod Superior to Avonex in Treating Relapsing MS in Phase 3 Trials, Celgene Reports

Celgene released the results of two Phase 3 trials showing that patients with relapsing multiple sclerosis (MS) who were treated with ozanimod had lower relapse rates...
22 November 2017 news autoimmune | FDA
Continue Reading →
Catalyst: 12th January 2026
Quotient

jcs-white.png

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

Facebook Linkedin
Journal For Clinical Studies © 2026, All Rights Reserved – Powered by Teksyte